SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. We are looking for talented, motivated, dynamic employees to join our international ...
SOTIO aims to become a diverse oncology company that develops early stage candidates into marketed immunotherapy products. We seek to add to our portfolio projects that are at advanced preclinical or clinical stages.
€1.18 billion acquisition provides for significant returns to PPF Group as NBE’s largest shareholder SOTIO, a clinical stage immuno-oncology company, and a member of PPF Group, continues ...
SO-C101 is an IL-15 superagonist that has been precisely designed and optimized for its use as a potent immunotherapy. It is currently being studied in an ongoing Phase 1/1b study …
DCVAC is a cell therapy platform designed to improve cancer outcomes by targeting multiple antigens and applying an immune-stimulatory technique. Multiple DCVAC candidates are in the clinical development …
SOTIO’s proprietary antibody-drug conjugate (ADC) platform yields potent and highly stable ADCs with a wide therapeutic window for the treatment of cancer …